logo
Bagel Recall Update As FDA Issues Highest Risk Warning

Bagel Recall Update As FDA Issues Highest Risk Warning

Newsweek3 days ago

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A number of recalled bagel products made by a Utah-based company have been issued a Class I risk classification by the U.S. Food and Drug Administration (FDA).
New Grains Gluten Free Bakery issued a voluntary recall for a variety of its bagels and breads in May due to the potential undeclared presence of egg—a major food allergen.
Newsweek contacted New Grains Gluten Free Bakery for comment via online contact form on Monday.
Why It Matters
A Class I recall is the highest risk level and is issued when there is a "reasonable probability" that the use of or exposure to a product could "cause serious adverse health consequences or death."
The FDA announcement, posted on the FDA's website, warned that people who have an allergy or severe sensitivity to eggs "run the risk of serious or life-threatening allergic reactions if they consume these products."
Eggs are one of the nine major food allergens as set out in law, which also include milk, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame.
"Food allergic reactions vary in severity from mild symptoms involving hives and lip swelling to severe, life-threatening symptoms, often called anaphylaxis, that may involve fatal respiratory problems and shock," says the FDA.
What To Know
The company, based in Spanish Fork, Utah, issued a recall for four of types of bagels, all gluten free—plain, cinnamon raisin, blueberry, and multigrain. According to the FDA, 100 units of each type of bagel were affected.
The recall was initiated after it was discovered that the products containing allergens, including eggs, were distributed with labels that did not reveal the presence of said allergens.
Additionally, the company has recalled the following bread products due to the undeclared presence of egg:
Artisan White Bread
Artisan Multigrain Bread
Artisan Sourdough Bread
Artisan Cinnamon Raisin Bread
A stock image of bread loaves.
A stock image of bread loaves.The products were distributed between April 4 and 21 under the lot numbers 90-107. The 32oz bread products were packaged in clear, vacuum-sealed plastic bags. A total of 250 units of each product were distributed to retail locations in Utah.
The recall announcement said that no illnesses had been reported.
What Happens Next
The recall is listed as ongoing, according to the FDA. Consumers who have purchased the products are urged not to consume them and to return them to the place of purchase for a full refund.
Separately, products from three different companies have been removed from shelves over the span of four days due to salmonella contamination fears, Newsweek reported on Friday.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Oral health continues to be a challenge in Arkansas
Oral health continues to be a challenge in Arkansas

Yahoo

timean hour ago

  • Yahoo

Oral health continues to be a challenge in Arkansas

LITTLE ROCK, Ark. – Brushing, flossing and annual dental checkups are very important, but officials say oral care in Arkansas continues to be a problem. Officials with the ADH Oral Health Program said Arkansas has many rural areas, and access to oral health care for people who live in rural areas can be challenging due to longer driving distances to care and other factors such as insurance coverage. Arkansas also has some counties that have been federally designated as dental provider shortage areas, which means there are not enough dentists to care for the population residing in the county. FDA Signals major shift on fluoride treatments for children Dental Director for Delta Dental of Arkansas, a dental benefits company, Niki Carter says after and during COVID oral health care became bad nationwide. However, last year Arkansas was ranked low for poor oral care. 'Arkansas is 50th in the nation, so we have our work cut for us,' Carter said. Carter explained that one way there's a gap in care has to do with distribution. '60% of dentists practice in only eight of the state's 75 counties and these eight counties represent 40% of the state's population that are all in urban areas,' Carter said. 'Technically, 60% of the population lives in rural areas.' Carter said that's not the only problem, the other issue is a shortage of dentists. 'Technically, there is a shortage of dentists per 100,000 population in our state,' Carter said. Study ranks Arkansas at the absolute bottom for dental health Carter says most dentists want to practice in metropolitan areas, which is why she's glad Lyon College will open the state's first dental school this month. 'One aspect of poor oral health is it affects numerous systemic illnesses,' Carter said. She also says students could go through a loan repayment program helping serve those needed areas. 'New dental students are graduating with $300,000 and $400,000 in debt. Through the repayment program, they will go to these rural areas and practice for a certain amount of time and pay back that loan,' Carter said. Carter says they also partner with multiple companies that provide care to patients, hoping they can help close the gap. One of the partners is Teledentistry, where members have 24/7 access to dental visits. Lyon College holds groundbreaking for first dental school in Arkansas Officials with the Arkansas Department of Health Office of Oral Health also say they're focused on promoting lifelong, optimum oral health for all Arkansans through education and prevention. This includes programming that educates health care providers about the interplay of oral health on systemic health, raising awareness about oral disease and the importance of regular dental care and programming that promotes and supports daily oral health hygiene habits for all ages, particularly children. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Semler Scientific, Inc. (SMLR) Faces Scrutiny from Edelson Lechtzin LLP
Semler Scientific, Inc. (SMLR) Faces Scrutiny from Edelson Lechtzin LLP

Yahoo

timean hour ago

  • Yahoo

Semler Scientific, Inc. (SMLR) Faces Scrutiny from Edelson Lechtzin LLP

On June 4, 2025, Edelson Lechtzin LLP announced that it has initiated an inquiry into whether the healthcare technology company, Semler Scientific, Inc. (NASDAQ:SMLR), misled investors about its business operations regarding claims tied to its QuantaFlo diagnostic device. A doctor in focus surrounded by colleagues in a hospital setting. In an annual report filed by Semler Scientific, Inc. (NASDAQ:SMLR) on February 28, 2025, the company disclosed that the U.S. Department of Justice (DOJ) was evaluating a potential False Claims Act case. The report triggered immediate market reaction, with the company's shares plummeting by 9.4% to close at $38.89 on March 3. Initiating the inquiry, Edelson Lechtzin LLP has asked for the public and stakeholders' help. Edelson urges those with non-public information regarding Semler Scientific, Inc. (NASDAQ:SMLR) to come forward and assist them in the investigation. It also encourages the company's investors who have suffered losses to follow the inquiry to learn more. The investor confidence has been significantly fluctuating since the disclosure. The stock's performance, which gained 6.49% last month, declined by 13.46% last week. The California-based company, Semler Scientific, Inc. (NASDAQ:SMLR), is known for developing non-invasive medical tools, with QuantaFlo being its most prominent product. Focusing on early disease detection and chronic condition management, the company has positioned itself between healthcare and technology. While we acknowledge the potential of SMLR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ByteBrain Launches MEDRAIL: AI System to Accelerate and Safeguard Clinical Trials
ByteBrain Launches MEDRAIL: AI System to Accelerate and Safeguard Clinical Trials

Business Upturn

time2 hours ago

  • Business Upturn

ByteBrain Launches MEDRAIL: AI System to Accelerate and Safeguard Clinical Trials

Sheridan, Wyoming, June 05, 2025 (GLOBE NEWSWIRE) — ByteBrain LLC, an emerging AI research and consulting firm , has announced the launch of MEDRAIL, an intelligent platform designed to help pharmaceutical companies run faster, safer, and more adaptive clinical trials. ByteBrain MEDRAIL, short for MEDical Reinforcement-based Agentic Intelligence for Lifesciences, brings together the power of artificial intelligence and advanced compliance automation to modernize the clinical trial process. The company has filed for a U.S. patent under the USPTO's Track One program to fast-track protection of the platform's novel technology. Priyanshu Sharma, co-founder of ByteBrain 'Clinical trials are often slow, costly, and difficult to manage, especially in fast-evolving medical landscapes,' said Priyanshu Sharma, Co-Founder of ByteBrain. 'MEDRAIL helps organizations react to safety data faster, reduce manual errors, and stay compliant with global regulatory standards.' A Smarter Way to Run Clinical Trials MEDRAIL uses a team of specialized AI agents, each trained to handle tasks like patient recruitment, protocol monitoring, safety surveillance, and documentation compliance. These agents work together in real time, adjusting to trial data and new regulatory guidelines as they emerge. Priyanshi Bhatnagar, co-founder of ByteBrain 'What makes MEDRAIL unique is its built-in safety verification and explainability,' added Priyanshi Bhatnagar, Co-Founder. 'Every protocol change, every recommendation, it's backed by formal logic, transparent reasoning, and a full audit trail.' Key Benefits of MEDRAIL: Faster protocol design and amendments Early detection of safety issues using AI Built-in compliance with FDA, HIPAA, and ICH-GCP standards Automated documentation with complete audit logs Seamless integration with existing clinical workflows Why It Matters Clinical trials can cost up to $3 billion per approved drug and take more than a decade to complete. ByteBrain believes that smarter, AI-assisted trial systems can cut that time significantly, potentially saving millions and accelerating time-to-market for life-saving therapies. The platform was developed with input from clinical research experts across pharma, academic medical centers, and regulatory affairs. Initial feedback has been positive, with ByteBrain preparing to release technical papers and pilot studies in the coming months. About ByteBrain ByteBrain LLC is a research-first AI company specializing in complex, regulated industries . Based in the U.S., it combines consulting services with the development of advanced IP in healthcare, finance, and enterprise AI systems. MEDRAIL is the firm's flagship healthtech innovation and part of its broader mission to build human-centered, compliance-ready AI solutions. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store